Status:
COMPLETED
Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
Lead Sponsor:
Pfizer
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the HDL-C increase and non-HDL lowering effect of torcetrapib/atorvastatin vs. fenofibrate.
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Diagnosis of Fredrickson Type IIB dyslipidema (Mixed Hyperlipidemia)
- Men and women at least 18 years of age
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT00139061
Start Date
March 1 2005
End Date
May 1 2006
Last Update
October 31 2007
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Angers, France, 49 000
2
Pfizer Investigational Site
Angers, France, 49 100
3
Pfizer Investigational Site
Bordeaux Cauderan, France, 33 200
4
Pfizer Investigational Site
Briollay, France, 49125